Discussion in 'BioMedical ME/CFS Research' started by Sly Saint, Feb 24, 2020.
full paper here
I see one of the studies they used was Reeves et al 2007. This used the so-called empiric criteria for CFS (Reeves et al, 2005), which are really rubbish. It found a prevalence of 2.54%.
Edited to add:
The Reeves et al 2005 criteria are an operationalisation of the Reeves et al 2003 criteria which are basically a version of the Fukuda 1994 criteria.
The venn diagram in Figure 5 is funny, shows the mess of case criteria based simply on symptom lists.
Agh! I wish they had separated the definitions according to whether PEM is a required criterion. This would have been informative, though I'm not sure many studies have used the IOM, CCC or ICC criteria.
Is the Holmes (CDC-1988) definition much different than Fukuda (CDC-1994)? Both list PEM as a minor symptom after all.
ETA: in a nutshell, Holmes seems to be Fukuda minus PEM but with more exclusions and many more "minor" symptoms. So in the absence of these symptoms -- even though they're not required -- I suppose that patients and clinicians alike would tend to investigate another diagnosis than CFS, thus leading to a lesser prevalence w/ Holmes?
.9% is about triple the prevalence of MS and about 2X the prevalence of RA. There’s maybe 15-20 drugs available for these 2 diseases combined. If the prevalence of MECFS was this high pharma would be going crazy to get drugs approved for this disease.
There are not easy targets with this illness yet as the pathophysiology is not understood.
So the drug companies are reluctant to invest at this time.
I think whatever the true prevalence is, the illness is significant enough that there is a big drug market there.
We just need to seek to ensure that the basics are understood more which will require more public and private funding.
Most of the work identifying drugs and drug targets is not done by pharmaceutical companies, who basically wait until most of the research is already done before jumping in and figuring out how a drug can be manufactured on an industrial scale.
Separate names with a comma.